Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal

被引:86
作者
Cassinotti, Andrea [1 ]
Actis, Giovanni C. [2 ,3 ]
Duca, Piergiorgio [4 ]
Massari, Alessandro [1 ]
Colombo, Elisabetta [5 ]
Gai, Elisa [6 ]
Annese, Vito [5 ]
Albasio, Giuseppe D' [6 ]
Manes, Gianpiero [1 ]
Travis, Simon [7 ]
Porro, Gabriele Bianchi [1 ]
Ardizzone, Sandro [1 ]
机构
[1] L Sacco Univ Hosp, Gastroenterol Unit, Dept Clin Sci, I-20157 Milan, Italy
[2] Gradenigo Hosp, Dept Gastrohepatol, Turin, Italy
[3] Molinette Mauriziano Hosp, Dept Gastroenterol, Turin, Italy
[4] Univ Milan, Sect Med Stat & Biometry, Milan, Italy
[5] Casa Sollievo della Sofferenza IRCSS, Gastroenterol Unit, San Giovanni Rotondo, Italy
[6] Careggi Hosp, Gastroenterol Unit, Florence, Italy
[7] John Radcliffe Hosp, Gastroenterol Unit, Oxford OX3 9DU, England
关键词
INFLAMMATORY-BOWEL-DISEASE; RANDOMIZED CONTROLLED-TRIAL; CROHNS-DISEASE; SHORT-TERM; REMISSION; MANAGEMENT; 5-AMINOSALICYLATES; 6-MERCAPTOPURINE; DEPENDENCY; DIAGNOSIS;
D O I
10.1038/ajg.2009.410
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Whether the duration of maintenance treatment with azathioprine (AZA) affects the outcome of ulcerative colitis (UC) is unclear. We investigated clinical outcomes and any predictive factors after withdrawal of AZA in UC. METHODS: In this multicenter observational retrospective study, 127 Italian UC patients, who were in steroid-free remission at the time of withdrawal of AZA, were followed-up for a median of 55 months or until relapse. The frequency of clinical relapse or colectomy after AZA withdrawal was analyzed according to demographic, clinical, and endoscopic variables. RESULTS: After drug withdrawal, a third of the patients relapsed within 12 months, half within 2 years and two-thirds within 5 years. After multivariable analysis, predictors of relapse after drug withdrawal were lack of sustained remission during AZA maintenance (hazard ratio, HR 2.350, confidence interval, CI 95% 1.434-3.852; P = 0.001), extensive colitis (HR 1.793, CI 95% 1.064-3.023, P = 0.028 vs. left-sided colitis; HR 2.024, CI 95% 1.103-3.717, P = 0.023 vs. distal colitis), and treatment duration, with short treatments (3-6 months) more disadvantaged than > 48-month treatments (HR 2.783, CI 95% 1.267-6.114, P = 0.008). Concomitant aminosalicylates were the only predictors of sustained remission during AZA therapy (P = 0.009). The overall colectomy rate was 10%. Predictors of colectomy were drug-related toxicity as the cause of AZA withdrawal (P = 0.041), no post-AZA drug therapy (P = 0.031), and treatment duration (P < 0.0005). CONCLUSIONS: Discontinuation of AZA while UC is in remission is associated with a high relapse rate. Disease extent, lack of sustained remission during AZA, and discontinuation due to toxicity could stratify relapse risk. Concomitant aminosalicylates were advantageous. Prospective randomized controlled trials are needed to confirm whether treatment duration is inversely associated with outcome.
引用
收藏
页码:2760 / 2767
页数:8
相关论文
共 36 条
[1]   Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis [J].
Ardizzone, S ;
Maconi, G ;
Russo, A ;
Imbesi, V ;
Colombo, E ;
Porro, GB .
GUT, 2006, 55 (01) :47-53
[2]   Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis [J].
Ardizzone, S ;
Molteni, F ;
Imbesi, V ;
Bollani, S ;
Porro, GB .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1997, 25 (01) :330-333
[3]   Guidelines for the treatment of ulcerative colitis in remission [J].
Ardizzone, S ;
Molteni, P ;
Bollani, S ;
Porro, GB .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1997, 9 (09) :836-841
[4]   Gastroenterology 1 - Inflammatory bowel disease: cause and immunobiology [J].
Baumgart, Daniel C. ;
Carding, Simon R. .
LANCET, 2007, 369 (9573) :1627-1640
[5]   Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines [J].
Ben-Horin, S. ;
Goldstein, I. ;
Fudim, E. ;
Picard, O. ;
Yerushalmi, Z. ;
Barshack, I. ;
Bank, I. ;
Goldschmid, Y. ;
Bar Meir, S. ;
Mayer, L. ;
Chowers, Y. .
GUT, 2009, 58 (03) :396-403
[6]   Predictors of clinical response to systemic steroids in active ulcerative colitis [J].
Bernal, Isabel ;
Manosa, Miriam ;
Domenech, Eugeni ;
Garcia-Planella, Esther ;
Navarro, Merce ;
Lorenzo-Zuniga, Vicente ;
Cabre, Eduard ;
Gassull, Miquel Angel .
DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (08) :1434-1438
[7]   Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment [J].
Bresci, G. ;
Parisi, G. ;
Capria, A. .
COLORECTAL DISEASE, 2008, 10 (08) :814-817
[8]   Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up [J].
Bresci, G ;
Parisi, G ;
Bertoni, M ;
Capria, A .
DIGESTIVE AND LIVER DISEASE, 2002, 34 (06) :419-423
[9]   LONG-TERM NEOPLASIA RISK AFTER AZATHIOPRINE TREATMENT IN INFLAMMATORY BOWEL-DISEASE [J].
CONNELL, WR ;
KAMM, MA ;
DICKSON, M ;
BALKWILL, AM ;
RITCHIE, JK ;
LENNARDJONES, JE .
LANCET, 1994, 343 (8908) :1249-1252
[10]   Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism [J].
de Boer, Nanne K. H. ;
Wong, Dennis R. ;
Jharap, Bindia ;
de Graaf, Peer ;
Hooymans, Piet M. ;
Mulder, Chris J. J. ;
Rijmen, Frank ;
Engels, Leopold G. J. B. ;
van Bodergraven, Adrian A. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (12) :2747-2753